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Abstract The effects of growth hormone (GH) replace-
ment on plasma lecithin:cholesterol acyltransferase (LCAT),
cholesteryl ester transfer protein (CETP), and phospho-
lipid transfer protein (PLTP), factors involved in high den-
sity lipoprotein (HDL) metabolism, are unknown. We car-
ried out a 6 months study in 24 GH-deficient adults who were
 
randomized to placebo (n 
 
5
 
 8), low dose GH (1 U daily,
n 
 
5
 
 8), and high dose GH (2 U daily, n 
 
5
 
 8), followed by a 6
months open extension study with high dose GH (1 drop-
out). No significant changes in plasma lipoproteins, LCAT,
CETP, and PLTP activities, cholesterol esterification (EST)
and cholesteryl ester transfer (CET) were observed after
placebo. After 6 months of GH (combined data, n 
 
5
 
 24),
very low 
 
1
 
 low density lipoprotein (VLDL 
 
1
 
 
 
LDL) choles-
terol (
 
P
 
 
 
,
 
 0.05) and apolipoprotein B (
 
P
 
 
 
,
 
 0.05) decreased,
whereas HDL cholesterol and HDL cholesteryl ester in-
creased (
 
P
 
 
 
,
 
 0.05). Prolonged treatment showed compa-
rable effects. Plasma apolipoprotein A-I and Lp[a] remained
 
unchanged. Plasma LCAT (
 
P
 
 
 
,
 
 0.01) and CETP activities
 
(
 
P
 
 
 
,
 
 0.01), as well as EST (
 
P
 
 
 
,
 
 0.01) and CET decreased (
 
P
 
 
 
,
 
0.01) after 12 months of GH (n 
 
5
 
 15), but PLTP activity did
not significantly change. Changes in EST and CET after 12
months of treatment were independently related to changes
in plasma LCAT (
 
P
 
 
 
5
 
 0.001 and CETP activity (
 
P
 
 
 
5
 
 0.01).
In conclusion, GH replacement therapy improves the lipo-
protein profile in GH-deficient adults. Chronic GH replace-
ment lowers plasma LCAT and CETP activities, contributing
to a decrease in cholesterol esterification and cholesteryl es-
ter transfer. These effects may have consequences for HDL
 
metabolism and reverse cholesterol transport.
 
—Beentjes,
J. A. M., A. van Tol, W. J. Sluiter, and R. P. F. Dullaart.
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Epidemiological studies have demonstrated that cardio-
vascular mortality is increased in adult patients with hy-
popituitarism (1–3). Indeed, media thickness of the ca-
 
rotid artery intima is increased in hypopituitary patients,
representing an early sign of atherosclerosis (4). It has
been suggested that this increased cardiovascular risk is, at
least in part, attributable to growth hormone (GH) defi-
ciency (1, 5). In adults, GH deficiency is associated with
unfavorable abnormalities in plasma lipoproteins, includ-
ing high plasma total and low density lipoprotein (LDL)
cholesterol concentrations, high plasma triglycerides, and
low high density lipoprotein (HDL) cholesterol levels (5).
Several studies have shown that GH replacement therapy
is able to lower plasma total and LDL cholesterol, particu-
larly in patients with adult-onset GH deficiency, without af-
fecting plasma triglycerides (5, 6). In GH-deficient adults,
HDL cholesterol increases, remains unchanged, or may
even decrease after GH replacement (5–7).
HDL is crucially involved in the process of reverse cho-
lesterol transport, whereby cholesterol is transported
from peripheral cells back to the liver, where it is metabo-
lized and excreted in the bile (8, 9). Apart from the action
of lipases, intravascular HDL metabolism and remodelling
is governed by lecithin:cholesterol acyltransferase (LCAT)
and lipid transfer proteins (8, 10–12). Plasma LCAT ester-
ifies free cholesterol to cholesteryl esters in HDL, whereas
cholesteryl ester transfer protein (CETP) transfers these
cholesteryl esters to very low density lipoproteins (VLDL)
and LDL, thereby decreasing the HDL cholesteryl ester
content (8–12). Another lipid transfer protein, phospho-
lipid transfer protein (PLTP), transfers phospholipids be-
tween lipoproteins and is able to convert HDL into
smaller and larger particles (13–15). During this process,
small apolipoprotein (apo) A-I-rich, pre-
 
b
 
 HDL particles
 
Abbreviations: apo, apolipoprotein; CETP, cholesteryl ester transfer
protein; GH, growth hormone; HDL, high density lipoproteins; IGF-I,
insulin-like growth factor I; LCAT, lecithin:cholesterol acyltransferase;
LDL, low density lipoproteins; Lp[a], lipoprotein [a]; PLTP, phospho-
lipid transfer protein; VLDL, very low density lipoproteins.
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are produced that may function as initial acceptors of free
cholesterol from cell surfaces and provide the initial
LCAT substrate (15, 16).
Current knowledge about the effect of GH on plasma
LCAT and lipid transfer protein regulation is limited. In
one study, plasma CETP activity was found to be increased
in acromegalic patients (17). In a cross-sectional study in-
cluding GH-deficient acromegalic and healthy male sub-
jects, in contrast, we recently found a negative relationship
between plasma insulin-like growth factor-I (IGF-I) and the
plasma activity levels of LCAT, CETP, and PLTP (18). In
view of these results it was hypothesized that GH replace-
ment would decrease plasma LCAT and lipid transfer pro-
tein activity levels in GH-deficient adults. In 24 GH-deficient
adults, we evaluated the effect of GH replacement on
plasma LCAT, CETP, and PLTP activity levels, measured with
exogenous substrates, in a 6-month placebo-controlled study,
followed by a 6-months open extension period. Changes in
plasma LCAT and lipid transfer proteins were the primary
endpoints of the study. Furthermore, we documented the ef-
fect of this treatment on plasma cholesterol esterification
and cholesteryl ester transfer between HDL and VLDL 
 
1
 
LDL, measured with endogenous plasma substrates.
SUBJECTS AND METHODS
 
Subjects and study design
 
The study was approved by the medical ethics committee of
the University Hospital Groningen, The Netherlands, and all pa-
tients provided written informed consent. Twenty-four adults
(minimal age 21 years) with childhood or adult-onset GH defi-
ciency were included. GH deficiency was defined as peak serum
GH levels in response to insulin-induced hypoglycemia 
 
,
 
5 
 
m
 
g/l
(10 mU/l) with a venous blood glucose nadir 
 
<
 
2.2 mmol/l and
the presence of hypoglycemic symptoms. Regular insulin was in-
travenously administered in a dose of 0.15 to 0.20 U/kg body
weight (19). The insulin tolerance test was per formed within 3
months prior to the study. Causes of GH deficiency were non-
functioning pituitary macroadenoma (n 
 
5
 
 10), craniopharyngi-
oma (n 
 
5
 
 4), macroprolactinoma (n 
 
5
 
 1), teratoma (n 
 
5
 
 1),
dysgerminoma (n 
 
5
 
 1), and idiopathic (n 
 
5
 
 7). Two patients
had been previously treated with GH, which was stopped more
than 5 years before entry in the present study. The median dura-
tion of GH deficiency before entry was 8.5 (range 2–46) years.
Twenty-three patients were on stable l-thyroxin replacement
therapy (125 to 175 
 
m
 
g daily), 17 received glucocorticoids (corti-
sone acetate 25 to 37.5 mg daily), and all men and 10 women
used sex steroids (Sustanon
 
®
 
 250 mg intramuscular per 3 to 4
weeks or various combinations of estrogens and progestagens).
Two postmenopausal women did not receive sex steroids. Six pa-
tients used desmopressin. In all participants, serum-free thyroxin
and triiodothyronine levels remained within the reference
range, and it was not necessary to adjust the l-thyroxin dose dur-
ing follow-up in any of the patients. Moreover, substitution ther-
apy with glucocorticoids and sex steroids was kept unchanged.
Diabetes mellitus (fasting venous blood glucose 
 
>
 
6.1 mmol/l),
hypertension (systolic blood pressure 
 
.
 
160 mmHg and diastolic
blood pressure 
 
.
 
95 mmHg), liver function abnormalities, kid-
ney disease (elevated serum creatinine or proteinuria 
 
.
 
300 mg/l),
clinically manifest cardiovascular disease and intention to be-
come pregnant were exclusion criteria.
The participating men and women were randomized sepa-
rately to low dose GH replacement (n 
 
5
 
 8, 1 U of Genotropin
 
®
 
,
Pharmacia & Upjohn Inc., Sweden, subcutaneously per day at
bedtime), high dose GH replacement (n 
 
5
 
 8, 2 U of GH per
day), or placebo (n 
 
5
 
 8) during 6 months in a double blind fash-
ion. Thus, there were 4 men and 4 women in each group. There-
after, GH treatment was continued or started in a 6 months open
extension period. GH and corresponding placebo administra-
tion was initiated in a dose of 1 U per day to avoid side effects,
and increased after 4 weeks to 2 U per day in those patients allo-
cated to the high dose treatment. As a consequence of the dou-
ble blind study design, GH was also started in a dose of 1 U per
day and then increased to 2 U per day in all patients in the ex-
tension study. One patient, initially allocated to low dose GH,
dropped out in the extension period.
Body mass index (BMI) was calculated as weight divided by
height squared. The waist/hip (W/H) ratio was measured as the
ratio of the smallest girth between rib cage and iliac crest and
the largest girth between waist and thigh (20). Bioelectrical im-
pedance analysis (BIA) was measured with a tetrapolar BIA ana-
lyzer (RJL Systems, Detroit, MI). After application of an alternat-
ing current of 800 
 
m
 
A at 50 kHz, resistance and reactance were
measured (21). Fat free mass was estimated with the manufac-
turer provided equation. Body fat mass was calculated by sub-
tracting fat free mass from body weight.
The participants were studied at baseline and after 2, 6, 8 and
12 months of follow-up. On each occasion they were studied
after an overnight fast, while venous blood was obtained for mea-
surement of lipid parameters and hormone levels and body com-
position was determined as described above.
 
Laboratory measurements
 
Venous blood was collected into ethylenediaminetetraacetic
acid-containing tubes (1.5 mg/ml) and was directly placed on ice.
Plasma was obtained within 30 min by low speed centrifugation
for 15 min at 4
 
8
 
C. Samples were frozen at 
 
2
 
70
 
8
 
C until analysis. All
laboratory measurements were carried out in coded samples.
Lipids were measured in whole plasma and in the HDL-
containing supernatant fraction after precipitation of apolipo-
protein (apoB)-containing lipoproteins with polyethylene glycol-
6000 (22). VLDL 
 
1 
 
LDL were calculated as the difference between
whole plasma and the supernatant fraction. Total cholesterol was
measured by gas chromatography. Free cholesterol was assayed by
a modification of this method in which the hydrolysis step was
omitted (23). Esterified cholesterol was calculated as the differ-
ence between total and free cholesterol. Triglycerides were mea-
sured enzymatically. ApoA-I and apoB were assayed by immunotur-
bidimetry (Boehringer Mannheim, Germany, cat. nos. 726478 and
726494, respectively). Lp[a] was assayed by enzyme-linked immuno-
sorbent assay (Biopool AB, Umea, Sweden, cat. no. 610221).
The plasma LCAT activity level was assayed using excess exog-
enous substrate containing [
 
3
 
H]cholesterol as described (24).
Plasma LCAT activity varies linearly with the amount of plasma
in the incubation system. Plasma CETP activity was determined,
after removal of VLDL and LDL from each sample, using an iso-
tope assay that detects the transfer of [1-
 
14
 
C]oleate-cholesteryl
ester from labeled exogenous LDL to an excess of unlabeled
pooled normal HDL (24, 25). In the assay system LCAT is inhib-
ited with dithiobis-2-nitrobenzoic acid. Plasma CETP was calcu-
lated as the bi-directional transfer between labeled LDL and
HDL. The plasma LCAT and CETP activity levels so measured
are strongly correlated with their mass concentration in plasma
(26, 27). Plasma PLTP activity was measured in a liposome
vesicles–HDL system as described (24, 28). Plasma samples were
incubated with [
 
3
 
H]phosphatidylcholine-labeled liposomes and
excess pooled normal HDL. After the incubation the liposomes
were precipitated with a mixture of NaCl, MgCl
 
2
 
, and heparin in
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final concentrations of 230 mmol/l, 92 mmol/l, and 200 U/ml,
respectively. The plasma PLTP activity is linearly correlated with
the amount of plasma used in the incubation system and is not
influenced by the phospholipid transfer promoting properties
of CETP (28).
Plasma newly synthesized cholesteryl ester transfer (CET) was
assayed by a radioisotope method as previously described (29,
30). In short, [
 
3
 
H]cholesterol complexed to albumin was equili-
brated overnight at 4
 
8
 
C with plasma-free cholesterol. Subse-
quently, the plasma samples were incubated at 37
 
8
 
C for 3 h.
VLDL 
 
1 
 
LDL were then precipitated by addition of phospho-
tungstate/MgCl
 
2
 
. Lipids were extracted form the precipitate and
the cholesteryl esters were separated on silica columns, followed
by counting of radioactivity. The assay system is not influenced
by cholesterol esterification on LDL (
 
,
 
4% of total) (29). CET is
closely correlated with net cholesteryl ester mass transfer from
HDL to VLDL and LDL under conditions of LCAT inhibition
(31). CET can thus be regarded as an accurate estimate of cho-
lesteryl ester mass transfer in plasma. Plasma cholesterol esterifi-
cation (EST) was determined by measurement of [
 
3
 
H]choles-
terol esterification using the same incubation system as for the
CET assay (29, 30). For measurement of EST, plasma was incu-
bated at 37
 
8
 
C for 1 h. The cholesterol esterification rate is linear
with time for 5 h, indicating an excess of unesterified choles-
terol in the assay system (29). The plasma LCAT, CETP, and
PLTP activity assays as well as CET and EST measurements were
performed in duplicate using the same batches of substrate.
Plasma LCAT, CETP, and PLTP activity levels were related to hu-
man pool plasma and are expressed in arbitrary units (AU), corre-
sponding to the percentages of the activities in this pool plasma.
Plasma CET and EST were expressed in nmol/ml per h. The
within-assay coefficients of variation (CVs) of LCAT, CETP, PLTP,
CET, and EST are 4.5%, 2.7%, 3.5%, 7.1%, and 5.4%, respectively.
Blood glucose was analyzed on an APEC glucose analyzer
(APEC, Danvers, MA). Plasma IGF-I was measured by radioim-
munoassay after acid-ethanol extraction (Nichols Institute of Di-
agnostics, San Juan Capistrano, CA). The interassay CV of IGF-I
is 
 
,
 
8.5%. The reference range (
 
2
 
2 SD to 
 
1
 
2 SD of logarithmi-
cally transformed values) is 16 –89 nmol/l, 12–64 nmol/l, and
9–47 nmol/l at age 20, 40, and 60 years, respectively.
 
Statistical analysis
 
Parameters are given in medians (interquartile ranges) and
changes in parameters are given in medians (95% confidence
intervals). Between group differences in (changes in) parame-
ters were evaluated by Kruskal-Wallis analysis of variances.
Changes in parameters were evaluated by paired Wilcoxon tests
and by Friedmans’s two-way analysis of variance. Univariate rela-
tionships were evaluated by Spearmans’ rank correlation analysis
(R
 
s
 
). Multiple regression analysis was carried out to evaluate the
independent relationships between parameters. A two-sided 
 
P
 
value 
 
,
 
0.05 was considered to be significant.
 
RESULTS
As shown in 
 
Table 1
 
, age, as well as BMI, waist/hip ratio,
and fat mass at baseline were not significantly different in
the three groups. BMI and waist/hip ratio did not change
during active GH treatment (data not shown). In the low
dose GH group, fat mass decreased after 6 and 12 months.
The decrease in fat mass with high dose GH did not reach
significance (
 
P
 
 
 
5
 
 0.12 after 12 months), as a consequence
of improved appetite and modest weight gain in two pa-
tients. Baseline systolic arterial pressure was slightly higher
in the placebo group than in the high dose GH group.
Fasting blood glucose was similar in the groups at baseline
and did not change during GH treatment (data not
shown). Baseline plasma IGF-I was not significantly different
between the groups. As expected, plasma IGF-I remained
unaltered after placebo and rose during GH treatment.
Baseline plasma (apo) lipoprotein parameters, LCAT,
and lipid transfer protein activity levels, as well as plasma
EST and CET are shown in 
 
Table 2
 
. Baseline HDL choles-
terol, the HDL/VLDL 
 
1 
 
LDL cholesterol ratio, and plasma
triglycerides were lowest in the low dose GH group. As
shown in 
 
Table 3
 
, no significant changes in (apo)lipopro-
tein parameters were found after 6 months of placebo ad-
 
TABLE 1. Clinical characteristics, fasting blood glucose, and insulin-like growth factor-I (IGF-I) in growth 
hormone (GH)-deficient patients allocated to placebo, low dose GH (GH low) and high dose GH
(GH high) replacement therapy at baseline and after 6 months of followup,
followed by 6 months high dose GH replacement in all patients
 
Variable Placebo (n 
 
5
 
 8) GH Low (n 
 
5
 
 8) GH High (n 
 
5
 
 8)
 
Age (years) 52 (34–58) 37 (31–43) 42 (24–51)
Blood pressure (mmHg)
Systolic 134 (128–147)
 
a
 
127 (123–136) 125 (121–129)
Diastolic 82 (80–88) 78 (73–83) 80 (78–84)
Body mass index (kg/m
 
2
 
) 27.1 (26.2–31.8) 25.6 (24.4–28.3) 27.1 (25.5–29.5)
Waist/hip ratio 0.95 (0.91–0.96) 0.90 (0.83–0.95) 0.93 (0.92–0.96)
Fat mass (kg)
Baseline 25.8 (20.7–32.9) 22.1 (20.4–23.4) 29.1 (19.1–32.8)
6 months 25.0 (21.2–34.6) 19.4 (18.5–22.1)
 
c
 
24.6 (16.1–32.2)
12 months 23.7 (16.5–30.1)
 
c
 
18.9 (17.3–22.5)
 
c
 
25.8 (14.7–29.6)
Blood glucose (mmol/l) 4.0 (3.5–4.5) 4.4 (3.6–4.6) 4.1 (3.8–4.4)
Plasma IGF-I (nmol/l)
Baseline 11.5 (9.5–15.8) 5.8 (1.3–17.0) 14.8 (8.1–17.1)
6 months 11.4 (10.1–14.8) 24.0 (12.5–55.9)
 
c,d
 
39.6 (37.1–45.6)
 
c,d
 
12 months 35.3 (19.9–46.7)
 
b
 
27.9 (12.5–56.9)
 
c
 
43.2 (36.2–51.9)
 
c
 
Data expressed as medians (interquartile ranges).
 
a
 
P
 
 
 
,
 
 0.05 from high dose GH group; 
 
b
 
P
 
 
 
,
 
 0.05, 
 
c
 
P
 
 
 
,
 
 0.01 from baseline; 
 
d
 
P 
 
, 
 
0.05 from change with placebo.
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ministration. The effects of 6 months GH replacement ther-
apy on lipoprotein parameters are analyzed as the changes
after 6 months of active treatment in the combined patients,
representing the changes after 6 months of GH treatment
in the low and high dose GH group and after 6 months ac-
tive treatment in the extension period in the placebo group
(n 
 
5
 
 24, Table 3). The changes in (apo)lipoproteins after
high dose GH never exceeded those after low dose GH. Ta-
ble 3 also shows the changes in lipoprotein parameters after
12 months of active treatment compared to baseline in the
combined low and high dose GH groups (n 
 
5
 
 15). There
were no differences in the changes in lipoprotein parame-
ters after 12 months GH treatment compared to baseline
between the patients initially assigned to low dose (n 
 
5
 
 8)
and high dose GH treatment (n 5 7). Plasma total choles-
terol did not significantly change after 6 months and de-
creased after 12 months of GH treatment. VLDL 1 LDL
cholesterol and apoB levels decreased after 6 months as well
as after 12 months of GH replacement, whereas HDL cho-
lesterol tended to increase (P , 0.05 after 6 months of GH
and P 5 0.10 after 12 months). Plasma apoA-I remained un-
altered. As a result, the HDL/VLDL 1 LDL cholesterol ra-
tio and the plasma apoA-I/B ratio increased after 6 and 12
months of GH therapy. The increase in HDL cholesterol
after 6 months of active GH treatment was due to a rise in
the HDL cholesteryl ester (0.10, 95% confidence intervals
0.03 to 0.20 mmol/l, P , 0.02), whereas HDL free choles-
terol did not significantly change (data not shown). The
changes in HDL cholesteryl ester and free cholesterol after
12 months were not significant (data not shown). No effects
of GH replacement on plasma triglycerides and on plasma
Lp[a] were observed.
TABLE 2. Baseline plasma (apo)lipoproteins, lecithin:cholesterol acyltransferase (LCAT), cholesteryl
ester transfer protein (CETP), phospholipid transfer protein (PLTP) activity levels, as well as plasma
cholesterol esterification (EST) and cholesteryl ester transfer (CET) in growth hormone (GH)-deficient
patients allocated to placebo, low dose GH (GH low), and high dose GH (GH high) replacement therapy
Placebo (n 5 8) GH Low (n 5 8) GH High (n 5 8)
Total cholesterol (mmol/l) 5.54 (4.85–7.05) 5.93 (5.56–7.23) 7.08 (5.85–7.51)
VLDL 1 LDL cholesterol (mmol/l) 4.28 (3.86–6.19) 5.41 (4.66–6.32) 5.77 (4.78–6.33)
HDL cholesterol (mmol/l) 1.02 (0.79–1.26) 0.80 (0.69–0.97) 0.98 (0.89–1.44)a
HDL/VLDL 1 LDL cholesterol 0.24 (0.17–0.27)a 0.14 (0.12–0.18) 0.20 (0.14–0.29)a
Triglycerides (mmol/l) 1.17 (1.02–1.69) 1.00 (0.93–1.14) 1.67 (1.51–1.79)a
ApoA-I (g/l) 0.93 (0.87–1.04) 0.90 (0.80–1.02) 1.08 (0.92–1.14)
ApoB (g/l) 0.97 (0.82–1.13) 1.05 (0.91–1.18) 1.20 (1.10–1.27)
ApoA-I/apoB 0.87 (0.76–1.29) 0.84 (0.77–1.03) 0.89 (0.76–0.96)
Lp[a] (mg/l) 72 (23–304) 45 (21–152) 121 (76–218)
LCAT activity (AU) 66 (46–94) 89 (53–99) 96 (41–106)
CETP activity (AU) 42 (25–76) 70 (50–79) 57 (35–66)
PLTP activity (AU) 70 (47–93) 86 (64–92) 62 (50–101)
EST (nmol/ml/h) 15 (6–79) 35 (22–84) 71 (20–108)
CET (nmol/ml/h) 9 (4–30) 13 (9–24) 23 (12–42)
Data in medians (interquartile ranges).
a P , 0.05 from low dose GH group.
TABLE 3. Changes in plasma (apo)lipoproteins, lecithin:cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), 
phospholipid transfer protein (PLTP) activity levels, as well as plasma cholesterol esterification (EST) and cholesteryl ester transfer
(CET) after 6 months placebo administration, after 6 months active GH treatment, and after 12 months active GH treatment
Changes in Parameters
After 6 Months 
Placebo (n 5 8)
After 6 Months
GH (n 5 24)
After 12 Months 
GH (n 5 15)
Total cholesterol (mmol/l) 20.06 (20.53 to 0.32) 20.39 (20.81 to 0.09) 20.21 (21.05 to 20.03)b
VLDL 1 LDL cholesterol (mmol/l) 10.04 (20.43 to 0.36) 20.46 (20.91 to 20.05)a 20.49 (21.12 to 20.09)a
HDL cholesterol (mmol/l) 20.08 (20.13 to 0.01) 10.12 (0.01 to 0.22)a 10.09 (20.11 to 0.23)
HDL/VLDL 1 LDL cholesterol 20.01 (20.04 to 0.02) 10.05 (0.01 to 0.08)a 10.04 (0.01 to 0.10)a
Triglycerides (mmol/l) 10.04 (20.48 to 0.79) 10.13 (20.05 to 0.31) 10.02 (20.10 to 0.21)
ApoA-I (g/l) 10.04 (20.06 to 0.24) 10.05 (20.03 to 0.14) 10.02 (20.03 to 0.07)
ApoB (g/l) 10.05 (20.08 to 0.20) 20.12 (20.22 to 20.01)a 20.12 (20.29 to 20.01)b
ApoA-I/apoB 20.02 (20.12 to 0.05) 10.13 (0.07 to 0.22)c 10.16 (0.02 to 0.32)c
Lp[a] (mg/l) 140 (27 to 111) 121 (29 to 39) 116.5 (214.0 to 69.2)
LCAT activity (AU) 10.6 (230.3 to 15.6) 215.9 (234.6 to 7.4) 233.7 (253.7 to 213.4)c
CETP activity (AU) 21.7 (220.5 to 9.5) 211.9 (223.7 to 2.5) 222.7 (237.0 to 27.5)c
PLTP activity (AU) 24.0 (216.1 to 5.1) 13.3 (210.4 to 10.1) 211.6 (228.8 to 1.7)
PLTP/CETP activity 10.02 (20.14 to 0.24) 10.33 (20.03 to 0.65) 10.49 (0.10 to 0.84)a
EST (nmol/ml/h) 11.1 (238.6 to 7.3) 213.9 (241.9 to 1.9) 231.8 (261.4 to 210.7)c
CET (nmol/ml/h) 10.0 (212.9 to 2.8) 22.8 (212.0 to 3.4) 212.0 (218.7 to 23.8)c
Data in medians (95% confidence interval).
a P , 0.05; b P , 0.02; c P , 0.01 from before GH.
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Baseline plasma LCAT, lipid transfer protein activity lev-
els, EST, and CET were not significantly different among
the three groups at baseline (Table 2). Changes in these
parameters with placebo and during active GH replace-
ment therapy were analyzed as described above for (apo)
lipoprotein parameters. No significant changes in these pa-
rameters were found after placebo. As shown in Table 3,
the changes in plasma LCAT (P 5 0.18), CETP (P 5
0.09), EST (P 5 0.10), and CET (P 5 0.24) did not reach
significance after 6 months GH replacement (n 5 24),
whereas plasma PLTP activity remained unchanged (P 5
0.72). After 12 months of GH treatment, plasma LCAT
and CETP activity levels as well as plasma EST and CET
decreased. Plasma PLTP activity did not significantly
change (P 5 0.07). As a consequence, the ratio of plasma
PLTP/CETP activity increased after 12 months. The ob-
served effects of GH treatment on (apo)lipoproteins,
plasma LCAT, and lipid transfer protein activity levels as
well as on plasma EST and CET were essentially similar
when the averaged data at 2 and 6 months and at 8 and 12
months were used in the analyses (data not shown).
Univariate regression analysis showed no relationships
between the individual changes in serum free thyroxin and
free triiodothyronine levels and the changes in plasma
LCAT (Rs 5 0.25, P 5 0.35 and Rs 5 20.12, P 5 0.65, re-
spectively, n 5 15) and CETP activity levels (Rs 5 0.17, P 5
0.52 and Rs 5 0.19, P 5 0.48, respectively, n 5 15) after 12
months of active GH treatment. Multiple regression analy-
sis with the data obtained after 12 months of active GH
treatment showed that individual changes in plasma EST
were related to changes in plasma LCAT activity (r 5 0.75,
P 5 0.001, n 5 24) without significant contributions of
changes in VLDL 1 LDL cholesterol (P 5 0.59) and
plasma triglycerides (P 5 0.79). Changes in plasma CET
were related to changes in plasma CETP activity (r 5 0.63,
P 5 0.01, n 5 24) again without significant contributions
of changes in VLDL 1 LDL cholesterol (P 5 0.64) and
plasma triglycerides (P 5 0.41).
DISCUSSION
In adult GH deficiency, several but not all trials have
demonstrated a lowering in plasma total and LDL choles-
terol as well as in plasma apoB in response to GH replace-
ment therapy (6, 32–37), an effect which may persist for
up to 10 years of treatment (38). These previous studies
used a GH replacement dose of about 2.5 to 5 U/day. In
the present study, GH doses of 1 and 2 U/day were given,
resulting in median plasma IGF-I levels in the lower and
higher physiological range, respectively (39). A decrease
in VLDL 1 LDL cholesterol and apoB was observed after
6 and 12 months of GH replacement, whereas no such
changes were found after 6 months of placebo administra-
tion. Moreover, HDL cholesterol increased after 6 months
of treatment and tended to remain higher thereafter, re-
sulting in an increase in the HDL/VLDL 1 LDL choles-
terol ratio. The plasma apoA-I/B ratio also rose with GH
replacement. These (apo)lipoprotein changes were not
larger with high dose than with low dose GH, raising the
possibility that a GH dose of 1 U/day could be sufficient to
lower plasma apoB-containing lipoproteins. As expected
(32–37, 40–43), no changes in triglycerides were found.
Plasma Lp[a] did not significantly change after 6 and 12
months of GH in this study. For unknown reasons, plasma
Lp[a] has been variably reported to remain unchanged or
to increase in response to GH treatment (36, 40–42, 44).
Taken together, the present observations confirm and ex-
tend the general view that GH substitution ameliorates
the lipoprotein abnormalities associated with adult GH
deficiency, thereby possibly lowering cardiovascular risk in
this patient category.
A novel finding of the present study is that the plasma
activity levels of LCAT and CETP, as a measure of their
mass in plasma, decreased after 12 months of GH replace-
ment. Although a potential drawback of our study is that
the changes were only significant in the extension period
compared to baseline, these observations are in accord
with our hypothesis that GH, either directly or through an
effect on IGF-I, has the ability to lower the plasma levels of
these factors. No significant change in plasma PLTP activ-
ity was demonstrated. Consequently, the PLTP/CETP ac-
tivity ratio rose after 12 months of GH replacement. In
our observational study among GH-deficient, acromega-
lic, and healthy subjects, the negative correlation between
plasma IGF-I with lipid transfer protein activity levels was
stronger for CETP than for PLTP (18).
The mechanisms responsible for the effects of chronic
GH replacement on plasma LCAT and CETP activity levels
are unknown. LCAT is synthesized by hepatic tissue (45),
whereas adipose tissue and liver are sources of CETP in
human plasma (12, 46). GH administration stimulates
LDL receptor expression (47) and increases VLDL apoB
removal (48), probably contributing to its VLDL 1 LDL
cholesterol-lowering effect. Plasma CETP levels are posi-
tively correlated with LDL cholesterol in normo- and hy-
percholesterolemic subjects (11, 49), and decrease in con-
junction with LDL lowering in response to treatment with
the HMG-CoA reductase inhibitor, simvastatin (50). Thus,
the liver could represent a site responsible for CETP regu-
lation by GH. Among other tissues, adipose tissue may also
be involved in plasma CETP lowering, in view of the decrease
in fat mass after GH replacement. As yet it is unknown
whether GH administration could affect plasma LCAT and
CETP indirectly via an effect on insulin sensitivity.
It is important to note that even at baseline, plasma
LCAT and CETP activity levels were low in a considerable
number of GH-deficient patients compared to previously
reported data in healthy subjects (51, 52). This resulted in
considerable variation in baseline plasma LCAT and CETP
activity levels. The lowering of plasma LCAT and CETP activ-
ity levels by GH indicates that this treatment may accentu-
ate relative deficiencies of LCAT and CETP in hypopitu-
itary patients. In our cross-sectional study in GH-deficient,
acromegalic, and healthy subjects (18), we also observed
relatively low plasma LCAT and CETP activity levels in
GH-deficient patients, despite a negative correlation with
plasma IGF-I in the whole cohort. In a further study, it was
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found that glucocorticoid replacement therapy is proba-
bly associated with low plasma LCAT and CETP activity
levels (53). The majority of the presently studied hypopi-
tuitary patients received glucocorticoids, and almost all of
them were treated for hypothyroidism and hypogonadism.
This precludes a meaningful analysis of the effect of (treat-
ment for) other pituitary hormone deficiencies on the
plasma LCAT and CETP responses to GH replacement
therapy. Nonetheless, an important effect of GH on plasma
LCAT and CETP via an effect on thyroid hormones is un-
likely, because no relationships were found between indi-
vidual changes in thyroid hormone levels and the changes
in plasma LCAT and CETP.
Plasma cholesterol esterification and cholesteryl ester
transfer are governed by the plasma activity levels of LCAT
and CETP as such, as well as by the concentration and
composition of the lipoproteins involved in these pro-
cesses (11, 54). In the current study, plasma EST and CET
were significantly lowered after 12 months of GH replace-
ment therapy. The changes in plasma EST and CET were
strongly correlated with the changes in plasma LCAT and
CETP activity, without independent contributions of
changes in VLDL 1 LDL cholesterol and plasma triglycer-
ides. This would indicate that GH replacement influenced
the processes of cholesterol esterification and cholesteryl
ester transfer predominantly by lowering the plasma levels
of active LCAT and CETP, respectively.
The transfer of cholesteryl esters out of HDL is consid-
ered to affect HDL cholesterol and cholesteryl ester con-
centrations (11, 12, 30), as indicated by the increased
HDL cholesteryl ester content after experimental inhibi-
tion of plasma CETP in the rabbit (55), and the elevated
HDL cholesterol in humans with genetic CETP deficiency
(56). The decrease in plasma CET may thus have contrib-
uted to the rise in HDL cholesterol and cholesteryl ester
during GH replacement. Of note, cholesteryl ester trans-
fer out of HDL and cholesterol esterification in HDL are
thought to be integrated processes (57, 58), and the low-
ering in plasma CET could have induced a secondary de-
crease in plasma EST, even apart from the effect of GH re-
placement on plasma LCAT activity levels per se. It cannot
be excluded that GH replacement may have affected cho-
lesterol and other lipids in HDL by other mechanisms
than plasma CET, including effects on lipases. Posthep-
arin plasma hepatic lipase activity has been reported to de-
crease (59) or to remain unchanged (33) after treatment
with GH. It is also possible that GH replacement affects cel-
lular processes involved in peripheral cholesterol efflux
and hepatic cholesterol uptake via HDL (60, 61).
Accelerated plasma cholesteryl ester transfer has been
documented in dyslipidemic subjects without pituitary dis-
orders in association with an increased cardiovascular risk
(11, 12, 51, 54, 62). This could imply that the lowering in
plasma CET in response to GH replacement represents an
anti-atherogenic phenomenon. Plasma PLTP activity did
not significantly change. This would raise the possibility
that the ability of plasma to generate pre-b HDL particles,
which are thought to be important in cholesterol removal
from peripheral cells (15, 16, 63, 64), remains largely un-
affected by GH replacement, although hepatic lipase and
possibly CETP may also be involved in pre-b HDL forma-
tion (9, 65). On the other hand, decreases in plasma EST
and CET indicate a diminished capacity of plasma to ester-
ify cholesterol in HDL and to subsequently transfer choles-
teryl esters from HDL to VLDL and LDL, and, hence, may
imply an impairment in these steps of the process of reverse
cholesterol transport after GH replacement. The conse-
quences for atherogenesis of a decrease in plasma choles-
terol esterification and cholesteryl ester transfer in response
to GH could be dependent on the balance between the ef-
ficacy of hepatic metabolism of apoB-containing lipopro-
teins as opposed to direct non CETP-mediated delivery of
peripheral cell cholesterol to the liver via HDL (49, 66). In
this respect it is important that GH is able to up-regulate
hepatic LDL receptor activity (47).
In conclusion, GH replacement therapy in hypopitu-
itary adults lowers plasma cholesterol esterification and
cholesteryl ester transfer in conjunction with decreases in
plasma LCAT and CETP activity levels. These effects may
have consequences for HDL metabolism and for reverse
cholesterol transport.
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